KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Cost of Revenue (2016 - 2026)

Gsk has reported Cost of Revenue over the past 18 years, most recently at $2.5 billion for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 3.61% year-over-year to $2.5 billion; the TTM value through Mar 2026 reached $20.5 billion, up 3.08%, while the annual FY2025 figure was $12.0 billion, 3.28% up from the prior year.
  • Cost of Revenue for Q1 2026 was $2.5 billion at Gsk, down from $12.0 billion in the prior quarter.
  • Over five years, Cost of Revenue peaked at $12.0 billion in Q4 2025 and troughed at $2.4 billion in Q1 2023.
  • A 5-year average of $4.8 billion and a median of $2.9 billion in 2023 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: surged 198.5% in 2022 and later tumbled 35.22% in 2023.
  • Year by year, Cost of Revenue stood at $11.2 billion in 2022, then fell by 5.14% to $10.6 billion in 2023, then increased by 9.24% to $11.6 billion in 2024, then grew by 3.28% to $12.0 billion in 2025, then tumbled by 78.92% to $2.5 billion in 2026.
  • Business Quant data shows Cost of Revenue for GSK at $2.5 billion in Q1 2026, $12.0 billion in Q4 2025, and $3.0 billion in Q3 2025.